http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-907814-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J75-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J75-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J5-00 |
| filingDate | 1959-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1962-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-907814-A |
| titleOfInvention | Improvements in or relating to steroids and the manufacture thereof |
| abstract | The invention comprises a compound having the formula <FORM:0907814/IV (b)/1> wherein X11 is chlorine or fluorine, X111 is bromine, iodine, chlorine, fluorine, or hydrogen and R2 is a b -hydroxy or keto group, and the preparation thereof by treating the corresponding 21-iodo compound in which R2 is b -OH with a reducing agent and then, if desired, oxidising the compound so obtained to produce the corresponding 11-keto derivative. As reducing agent sodium thiosulphate or sodium or potassium bisulphite may be used. Oxidation may be effected with CrO3, N-bromoacetamide or N-bromosuccinimide.ALSO:Anti-inflammatory compositions comprising compounds having the formula <FORM:0907814/VI/1> wherein X11 is chlorine or fluorine, X111 is bromine, iodine, chlorine, fluorine or hydrogen and R2 is a b -hydroxy or keto group, with or without the addition of an antibiotic (e.g. neomycin sulphate, novobiocin, bacitracin, circulin, polymyxin B sulphate, gramicidin, streptomycin sulphate, dihydrostreptomycin, oxytetracycline, chlortetracycline, tetracycline or chloramphenicol) and/or a sulphonamide, and a pharmaceutical diluent, are employed orally, parenterally or topically in tablets, ointments, lotions, jellies, creams, suppositories, bougies or aqueous suspensions. An ointment exemplified, incorporating 2-fluoro-11b ,17a -dihydroxy - 4 - pregnene - 3,20 - dione may contain in addition neomycin sulphate. |
| priorityDate | 1958-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.